All Satellite Symposia, Presentation Theaters, and Learning Lounges preceding and following the official program IDWeek 2016 are independently organized and executed. IDWeek does not endorse or support the programming of any Symposia, Presentation Theater, or Learning Lounge.
Yehuda Carmeli, MD, MPH
Professor in Medicine, Tel Aviv University
Head, National Institute for Antibiotic Resistance and Infection Control
Tel Aviv Medical Center. Israel
Keith Rodvold, PharmD, F P, FIDSA
Professor of Pharmacy Practice and Pharmacy in Medicine
Colleges of Pharmacy and Medicine
Co-Director, Section of Infectious Diseases Pharmacotherapy
Department of Pharmacy Practice
University of Illinois at Chicago
Andrew F. Shorr, MD, MPH
Associate Chief, Pulmonary and Critical Care
Washington Hospital Center
Associate Professor of Medicine
Georgetown University Hospital
Describe the scope, prevalence and clinical implications of resistant Gram-negative pathogens.
Identify and understand the clinical impact of resistant Gram-negative bacteria and their various mechanisms of resistance on different types of infections and patient types in order to optimize treatment strategies.
List currently available and near-term pipeline treatment options for Gram-negative infections and how each of their profiles may help direct the selection of optimal antibiotic therapy in clinical practice.
Review the evolution of the newer antibiotics with a focus on aminoglycosides and how to optimize treatment strategies that include this class.
Center for Education Development designates this live educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™, 2.0 ANCC credits, or 2.0 CPE credits (NEED THE NUMBER).
Agenda subject to change and was provided by:
The Center for Education Development; 601 Route 206, 26-409; Hillsborough, NJ; 908-617-0177;Activitymanager@CEDevelopment.org.